Core Insights - Sotera Health Company reported strong financial results for the third quarter and first nine months of 2025, with significant revenue and income growth compared to the previous year [2][3][4]. Financial Performance - Third-quarter 2025 net revenues increased by 9.1% to $311 million, up from $285 million in the third quarter of 2024. On a constant currency basis, the increase was 8.0% [2][8]. - Net income for the third quarter of 2025 was $48 million, or $0.17 per diluted share, compared to $17 million, or $0.06 per diluted share in the same quarter of 2024 [2][8]. - Adjusted EBITDA for the third quarter of 2025 rose by 12.2% to $164 million, with an 11.2% increase on a constant currency basis [2][8]. - For the first nine months of 2025, net revenues grew by 6.2% to $860 million, with net income of $43 million, or $0.15 per diluted share, compared to $32 million, or $0.11 per diluted share in the same period of 2024 [3][8]. Business Segment Performance - Sterigenics segment reported net revenues of $193 million for the third quarter of 2025, a 9.8% increase, with segment income rising by 11.6% to $107 million [5][6]. - Nordion's net revenues increased by 22.4% to $63 million in the third quarter of 2025, with segment income up by 19.9% to $38 million [9][10]. - Nelson Labs experienced a decrease in net revenues by 5.0% to $56 million in the third quarter of 2025, but segment income increased by 1.9% to $19 million [11][12]. Outlook and Guidance - The company reaffirmed its 2025 revenue outlook, projecting growth in the range of 4.5% to 6.0% on a constant currency basis, and raised its Adjusted EBITDA growth outlook to 6.75% to 7.75% [4][16]. - The interest expense range was improved to $154 million to $158 million, and the tax rate applicable to Adjusted Net Income was adjusted to 29.00% to 31.00% [16][17]. Balance Sheet and Liquidity - As of September 30, 2025, Sotera Health had total debt of $2.2 billion and unrestricted cash of $299 million, with a Net Leverage Ratio improved to 3.3x [13][14]. - The company achieved a contractual net leverage target, resulting in a 25 basis point reduction in the interest rate on its First Lien Term Loan facility [14].

Core Viewpoint - Sotera Health Company will release its financial results for the third quarter ended September 30, 2025, on November 4, 2025, before market opening, followed by a conference call to discuss the results and operating highlights [1]. Company Overview - Sotera Health is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry [3]. - The company operates through three business segments: Sterigenics, Nordion, and Nelson Labs [3]. - Sotera Health is dedicated to its mission of safeguarding global health [3]. Conference Call Details - The conference call will take place at 9:00 a.m. Eastern Daylight Time on November 4, 2025 [1]. - Participants can join the call by dialing 1-844-481-2916 (toll-free in the U.S.) or 1-412-317-0709 for international calls [2]. - A live webcast of the conference call will be available on the company's website, along with accompanying materials, and a replay will be accessible later that day [2].

Core Insights - Sotera Health Company reported a 6.4% increase in net revenues for Q2 2025, reaching $294 million compared to $277 million in Q2 2024, with a constant currency increase of 6.0% [2][6] - The company experienced a net income of $8 million, or $0.03 per diluted share, which includes a pending settlement of approximately $34 million related to ethylene oxide claims [2][3] - Adjusted EBITDA for Q2 2025 rose by 9.8% to $151 million, with an adjusted earnings per diluted share of $0.20, an increase of $0.01 from the previous year [2][6] Financial Performance - For the first half of 2025, net revenues increased by 4.6% to $549 million, compared to $525 million in the same period of 2024, with a constant currency increase of 5.3% [3][6] - The company reported a net loss of $5 million for the first half of 2025, which includes settlements of approximately $31 million and $34 million related to ethylene oxide claims [3][6] - Adjusted EBITDA for the first half of 2025 increased by 9.3% to $273 million, with adjusted EPS rising by $0.01 to $0.33 compared to the first half of 2024 [3][6] Business Segment Performance - Sterigenics segment revenues grew by 10.5% to $195 million in Q2 2025, with segment income increasing by 11.3% to $108 million [5] - Nordion's net revenues increased by 2.9% to $42 million in Q2 2025, with segment income slightly rising to $23 million [8] - Nelson Labs experienced a 3.3% decrease in net revenues to $57 million in Q2 2025, but segment income increased by 13.9% to $20 million [10] Outlook and Guidance - The company raised its full-year 2025 revenue outlook to a growth range of 4.5% - 6.0% from a previous range of 4.0% - 6.0% [6][14] - Adjusted EBITDA growth outlook was also raised to 6.0% - 7.5% from 4.5% - 6.5% [6][14] - The expected tax rate applicable to adjusted net income improved to a range of 31.5% - 33.5% from 33% - 35% [14] Balance Sheet and Liquidity - As of June 30, 2025, Sotera Health had total debt of $2.3 billion and unrestricted cash of $332 million, compared to $2.3 billion in total debt and $277 million in cash at the end of 2024 [12] - The company's net leverage ratio improved to 3.5x as of Q2 2025, down from 3.7x at the end of 2024 [12][14]